In € million |
Notes |
2019 |
2018 |
Sales |
11,227 |
11,299 |
|
of which revenue from non-core activities |
983 |
1,042 |
|
of which net sales |
|
10,244 |
10,257 |
Cost of goods sold |
|
(8,244) |
(8,264) |
Gross margin |
|
2,983 |
3,035 |
Commercial costs |
|
(381) |
(373) |
Administrative costs |
|
(950) |
(1,006) |
Research and development costs |
|
(323) |
(297) |
Other operating gains and losses |
(131) |
(123) |
|
Earnings from associates and joint ventures |
95 |
44 |
|
Results from portfolio management and reassessments |
(914) |
(208) |
|
Results from legacy remediation and major litigations |
(61) |
(86) |
|
EBIT |
|
316 |
986 |
Cost of borrowings |
(140) |
(131) |
|
Interest on loans and short term deposits |
15 |
13 |
|
Other gains and losses on net indebtedness |
(16) |
(1) |
|
Cost of discounting provisions |
(105) |
(77) |
|
Income from equity instruments measured at fair value through other comprehensive income |
|
4 |
|
Profit for the year before taxes |
|
74 |
791 |
Income taxes |
(153) |
(75) |
|
Profit/(loss) for the year from continuing operations |
|
(79) |
716 |
Profit for the year from discontinued operations |
236 |
201 |
|
Profit for the year |
157 |
917 |
|
attributable to: |
|
|
|
Solvay share |
|
118 |
877 |
non-controlling interests |
|
38 |
39 |
Basic earnings per share from continuing operations (€) |
|
(1.14) |
6.55 |
Basic earnings per share from discontinued operations (€) |
|
2.29 |
1.94 |
Basic earnings per share (€) |
1.15 |
8.49 |
|
Diluted earnings per share from continuing operations (€) |
|
(1.14) |
6.52 |
Diluted earnings per share from discontinued operations (€) |
|
2.28 |
1.93 |
Diluted earnings per share (€) |
1.15 |
8.46 |
The comparative figures of income taxes have been restated (decrease of expense) for an amount of € 19 million, following amendments to IAS 12 Income Taxes as part of the annual improvements to IFRS standards 2015–2017 cycle – See section Basis of preparation.